Last reviewed · How we verify
Fuzheng Huayu tablet
Fuzheng Huayu tablet is a traditional Chinese medicine formulation that promotes liver fibrosis reversal and hepatic function recovery through anti-inflammatory and antifibrotic pathways.
Fuzheng Huayu tablet is a traditional Chinese medicine formulation that promotes liver fibrosis reversal and hepatic function recovery through anti-inflammatory and antifibrotic pathways. Used for Hepatic fibrosis and cirrhosis, Chronic hepatitis B with fibrosis, Chronic liver disease with fibrotic progression.
At a glance
| Generic name | Fuzheng Huayu tablet |
|---|---|
| Also known as | FZHY, Gan Ping, 319 Recipe |
| Sponsor | ShuGuang Hospital |
| Drug class | Traditional Chinese medicine herbal formulation |
| Modality | Small molecule |
| Therapeutic area | Hepatology |
| Phase | FDA-approved |
Mechanism of action
The tablet combines multiple herbal components designed to reduce hepatic inflammation, inhibit hepatic stellate cell activation, and promote apoptosis of activated fibroblasts. It works to improve microcirculation and enhance hepatocyte regeneration, thereby reversing established liver fibrosis and improving overall liver function in chronic liver disease.
Approved indications
- Hepatic fibrosis and cirrhosis
- Chronic hepatitis B with fibrosis
- Chronic liver disease with fibrotic progression
Common side effects
- Gastrointestinal upset
- Mild hepatic enzyme elevation
Key clinical trials
- Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (NA)
- Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu (PHASE2)
- Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis (PHASE2)
- Effects of Fuzheng Huayu Tablets on COVID-19 (PHASE4)
- Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir (PHASE4)
- Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir (PHASE4)
- Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir (PHASE4)
- Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fuzheng Huayu tablet CI brief — competitive landscape report
- Fuzheng Huayu tablet updates RSS · CI watch RSS
- ShuGuang Hospital portfolio CI